Prevalence of Perimyocarditis After Covid-19 Vaccine

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04865900

Enrollment

500

Registered

2021-04-29

Start date

2021-03-09

Completion date

2022-04-30

Last updated

2021-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perimyocarditis, Covid19

Brief summary

The aim of this study is to determine whether there is a higher prevalence of perimyocarditis after undergoing vaccination for Covid-19.

Interventions

DIAGNOSTIC_TESTLaboratory Blood Tests

Blood tests to determine liver and kidney functioning, total blood count, and troponin levels

DIAGNOSTIC_TESTECG

ECG to determine heart rate and functioning

DIAGNOSTIC_TESTPCR

PCR test to determine whether patient has Covid19

DIAGNOSTIC_TESTAntibody test

Antibody test to determine level of antibodies to Covid19

DIAGNOSTIC_TESTEchocardiography

If Troponin level elevated echocardiography to determine heart function

DIAGNOSTIC_TESTMRI

If Troponin level elevated MRI to determine heart function

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

16 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Patients planning Pfizer-BioNTech BNT162b2 vaccination against Covid19

Exclusion criteria

* Patients infected with Covid19

Design outcomes

Primary

Measure	Time frame	Description
Elevated Troponin	4 weeks	Laboratory blood tests will be taken before and after Covid19 vaccination and compared. Troponin levels above normal range of 0.4 ng/ml will indicate possibility of perimyocarditis and patient will referred for additional testing.

Countries

Israel

Contacts

Primary ContactElisabeth Mahajna, MA

liesma@hy.health.gov.il972-4-7744695

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026